PR Newswire
LAS VEGAS, March 16, 2026
The neuromyelitis optica spectrum disorder market size in the 7MM is expected to show positive growth during the forecast period (2026-2036), mainly attributed to the increasing prevalence of NMOSD, growing awareness, advancement in diagnostic techniques, and the launch of emerging therapies such as BAT4406F (Bio-Thera Solutions), Telitacicept (RC18) (RemeGen/Vor Bio), Divozilimab (BCD-132) (Biocad), and others, reports DelveInsight.
LAS VEGAS, March 16, 2026 /PRNewswire/ — Recently published Neuromyelitis Optica Spectrum Disorder Market Insights report includes a comprehensive understanding of current treatment practices, neuromyelitis optica spectrum disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Neuromyelitis Optica Spectrum Disorder Market Summary
- The total neuromyelitis optica spectrum disorder treatment market size is expected to grow positively by 2036 in the leading markets.
- The United States accounted for the largest NMOSD treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- The prevalence among females was 9.48 per 100,000, while among males it was 3.52 per 100,000. The study observed a female-to-male ratio of approximately 3.5:1 for NMOSD.
- Leading NMOSD companies, such as Bio-Thera Solutions, RemeGen, Vor Bio, Biocad, and others, are developing new NMOSD treatment drugs that can be available in the NMOSD market in the coming years.
- The promising NMOSD therapies in clinical trials include BAT4406F, Telitacicept (RC18), Divozilimab (BCD-132), and others.
Discover what is the current and projected global NMOSD market size @ https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market
Key Factors Driving the Growth of the Neuromyelitis Optica Spectrum Disorder Market
- Improved Diagnostic Capabilities: Advances in diagnostic tools, especially biomarker testing like AQP4-IgG and MOG-IgG assays, have significantly increased diagnostic accuracy and reduced delays in identifying NMOSD cases.
- Expansion of Targeted Therapeutic Options: The launch and approval of novel biologic therapies, such as monoclonal antibodies and complement inhibitors, that specifically target immune pathways in NMOSD have transformed treatment approaches, driving higher adoption and market demand.
- Launch of Emerging NMOSD Drugs: The dynamics of the NMOSD market are expected to change in the coming years due to the launch of emerging therapies such as BAT4406F (Bio-Thera Solutions), Telitacicept (RC18) (RemeGen/Vor Bio), Divozilimab (BCD-132) (Biocad), and others.
Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, said that the current treatment strategies for NMOSD encompass a multidisciplinary approach aimed at managing symptoms and enhancing quality of life. While there is no cure for NMOSD, interventions such as immunosuppressive therapy play a crucial role in the management of NMOSD. Recently approved therapies offer hope for future advancements in NMOSD treatment.
Neuromyelitis Optica Spectrum Disorder Market Analysis
- Current management strategies for NMOSD provide effective symptom control but do not offer a cure. Acute relapses are typically addressed using high-dose intravenous corticosteroids, such as methylprednisolone.
- Common long-term therapies include corticosteroids, azathioprine, mycophenolate mofetil, and rituximab, with azathioprine or mycophenolate mofetil often paired with low-dose steroids. For patients who do not respond adequately to intravenous corticosteroids during severe relapses, plasma exchange can be an effective alternative.
- In July 2025, NHS England introduced a national commissioning policy that recommends and funds the use of ACTEMRA (tocilizumab) for NMOSD patients who are unable to tolerate or have not responded to earlier treatments.
- ACTEMRA is delivered through specialised neurology centres under NHS England. Although tocilizumab had previously been authorized by the MHRA for several inflammatory conditions, it had not been specifically approved for NMOSD in the UK until this policy.
- In the United States, FDA-approved treatments for NMOSD include ENSPRYNG, ULTOMIRIS, and others.
- Additionally, emerging pipeline therapies, such as BAT4406F (Bio-Thera Solutions), Telitacicept (RC18) (RemeGen/Vor Bio), Divozilimab (BCD-132) (Biocad), and others, are contributing to ongoing innovation in the NMOSD treatment landscape.
Neuromyelitis Optica Spectrum Disorder Competitive Landscape
Some of the NMOSD drugs under development include BAT4406F (Bio-Thera Solutions), Telitacicept (RC18) (RemeGen/Vor Bio), Divozilimab (BCD-132) (Biocad), and others.
Bio-Thera Solutions’ BAT4406F is an investigational, Phase II glyco-engineered monoclonal antibody being studied in China. The treatment is designed to boost antibody-dependent cellular cytotoxicity (ADCC). As a type I anti-CD20 antibody, it promotes B-cell depletion through complement-dependent cytotoxicity while enhancing ADCC, and is currently under evaluation for autoimmune conditions such as NMOSD.
RemeGen/Vor Bio’s Telitacicept (RC18) is an innovative fusion protein developed for the treatment of autoimmune disorders. It is composed of the extracellular domain of the human TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) receptor fused to the Fc portion of human IgG. Telitacicept is engineered to block two signaling molecules essential to B-cell maturation, BLyS and APRIL.
Biocad’s BCD-132 (divozilimab) is a monoclonal antibody and a novel investigational therapy being developed for multiple sclerosis and other autoimmune conditions. Monoclonal antibodies are laboratory-engineered proteins modeled on the natural antibodies produced by the immune system, each designed to bind specifically to a particular target in the body.
For BCD-132, the target is the CD20 protein found on B cells. When BCD-132 attaches to CD20, it triggers the elimination of these B cells, lowering their numbers and thereby reducing immune activity associated with autoimmune diseases. Divozilimab’s safety and effectiveness have been evaluated in preclinical animal studies, and clinical trials in humans are currently ongoing.
The anticipated launch of these emerging therapies are poised to transform the NMOSD market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the NMOSD market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about are new drugs upcoming in NMOSD pipeline @ Neuromyelitis Optica Spectrum Disorder Drugs
What is Neuromyelitis Optica Spectrum Disorder?
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune condition in which the body’s immune system mistakenly attacks the central nervous system, primarily targeting the optic nerves and spinal cord. This leads to episodes of optic neuritis, causing vision loss or eye pain, and transverse myelitis, which can result in limb weakness, sensory changes, or problems with bladder and bowel control. NMOSD is often associated with antibodies against a protein called aquaporin-4 (AQP4), which helps distinguish it from similar conditions like multiple sclerosis. Because attacks can be severe and cause lasting disability, early diagnosis and long-term treatment to prevent relapses are essential for managing the disorder effectively.
Neuromyelitis Optica Spectrum Disorder Epidemiology Segmentation
The NMOSD epidemiology section provides insights into the historical and current NMOSD patient pool and forecasted trends for the leading markets. The diagnosed prevalence rate of NMOSD is estimated at nearly 1.5 per 100,000 population. Between 70-80% of NMOSD patients will have anti-AQP4 antibodies.
The NMOSD treatment market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:
- Total Prevalent Cases of NMOSD
- Total Diagnosed Prevalent Cases of NMOSD
- Gender-specific Diagnosed Prevalent Cases of NMOSD
- Treated Cases of NMOSD
Neuromyelitis Optica Spectrum Disorder Market Report Metrics
Details
Study Period
2022-2036
Coverage 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Neuromyelitis Optica Spectrum Disorder Epidemiology Segmentation Total Prevalent Cases of NMOSD, Total Diagnosed Prevalent Cases of NMOSD, Gender-specific Diagnosed
Prevalent Cases of NMOSD, and Treated Cases of NMOSD
Key Neuromyelitis Optica Spectrum Disorder Companies Bio-Thera Solutions, RemeGen, Vor Bio, Biocad, Genentech, Chugai Pharmaceuticals, AstraZeneca,
Alexion, and others
Key Neuromyelitis Optica Spectrum Disorder Therapies
BAT4406F, Telitacicept (RC18), Divozilimab (BCD-132), ENSPRYNG, ULTOMIRIS, SOLIRIS, and others
Scope of the
Neuromyelitis Optica Spectrum Disorder
Market Report
- Therapeutic Assessment: Neuromyelitis Optica Spectrum Disorder current marketed and emerging therapies
- Neuromyelitis Optica Spectrum Disorder Market Dynamics: Key Market Forecast Assumptions of Emerging Neuromyelitis Optica Spectrum Disorder Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Neuromyelitis Optica Spectrum Disorder Market Access and Reimbursement
Download the report to understand what market trends are shaping NMOSD over the next decade @ Neuromyelitis Optica Spectrum Disorder Market Analysis
Table of Contents
1 Neuromyelitis Optica Spectrum Disorder Market Key Insights
2 Neuromyelitis Optica Spectrum Disorder Market Report
Introduction
3
NMOSD Market Overview at a Glance
3.1 Market Share (%) Distribution of NMOSD by Therapies in the
7MM in 2025
3.2 Market Share (%) Distribution of NMOSD by Therapies in the
7MM in 2036
4
Methodology
5
Executive Summary
6
Key Events
7
Disease Background and Overview: NMOSD
7.1
Introduction
7.2
Classification
7.3
Causes
7.4
Signs and Symptoms
7.5
Pathophysiology
7.6
Clinical features
7.7
Diagnosis
7.8
Treatment and Management
8 Epidemiology and Patient Population of NMOSD in the 7MM
8.1
Key Findings
8.2
Assumptions and Rationale
8.3
Total Prevalent Cases of NMOSD in the 7MM
8.4 Total Diagnosed Prevalent Cases of NMOSD in the 7MM
8.5
The US
8.5.1
Total Prevalent Cases of NMOSD
8.5.2
Total Diagnosed Prevalent Cases of NMOSD
8.5.3 Gender-specific Diagnosed Prevalent Cases of NMOSD
8.5.4
Treated Cases of NMOSD
8.6
EU4 and the UK
8.7
Japan
9
NMOSD Patient Journey
10
Marketed NMOSD Therapies
10.1
Key Cross Competition
10.2
ENSPRYNG: Genentech/Chugai Pharmaceuticals
10.2.1
Product Description
10.2.2
Product Profile
10.2.3
Other Developmental Activities
10.2.4
Clinical Trials Information
10.2.5
Safety and Efficacy
10.3
ULTOMIRIS: AstraZeneca
10.4
SOLIRIS: Alexion/AstraZeneca
List to be continued in the final report.
11
Emerging NMOSD Therapies
11.1
Key Cross Competition
11.2
BAT4406F: Bio-Thera Solutions
11.2.1
Drug Description
11.2.2
Product Profile
11.2.3
Other Developmental Activities
11.2.4
Clinical Trials Information
11.2.5
Safety and Efficacy
11.3
Telitacicept (RC18): RemeGen/Vor Bio
List to be continued in the final report.
12
NMOSD: Market Analysis
12.1
Key Findings
12.2 Key Neuromyelitis Optica Spectrum Disorder Market Forecast
Assumptions
12.3 Neuromyelitis Optica Spectrum Disorder Market Outlook
12.4
Conjoint Analysis
12.5
Total Market Size of NMOSD in the 7MM
12.6
Market Size of NMOSD by Therapies in the 7MM
12.7 The US Neuromyelitis Optica Spectrum Disorder Market
12.8.1
Total Market Size of NMOSD
12.8.2
Market size of NMOSD by Therapies
12.8 EU4 and the UK Neuromyelitis Optica Spectrum Disorder Market
12.9 Japan Neuromyelitis Optica Spectrum Disorder Market
12.9.1
Total Market Size of NMOSD
12.9.2
Market size of NMOSD by Therapies
13
Key Opinion Leaders’ Views on NMOSD
14
NMOSD Market SWOT Analysis
15
NMOSD Market Unmet needs
16
Market Access and Reimbursement
16.1
The US
16.2
In EU4 and the UK
16.3
Japan
17
Acronyms and Abbreviations
18
Bibliography
19 Neuromyelitis Optica Spectrum Disorder Market Report
Methodology
Related Reports
Neuromyelitis Optica Spectrum Disorder Clinical Trial Analysis
Neuromyelitis Optica Spectrum Disorder
Pipeline Insight
–
2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NMOSD companies, including Bio-Thera Solutions, Bioray Laboratories, Nanjing Bioheng Biotech Co., Ltd., Nanjing IASO Biotherapeutics, Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Xiniao Biotech Co., Ltd., and others.
Multiple Sclerosis
Market
Multiple Sclerosis
Market Insights, Epidemiology, and Market Forecast
–
2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple sclerosis companies including Novartis, Sanofi, AB Science, Roche, Clene Nanomedicine, InnoCare Pharma, and others.
Relapsing-Remitting Multiple Sclerosis
Market
Relapsing-Remitting Multiple Sclerosis
Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key RRMS companies including Mapi Pharma, Apimeds, Genentech (Roche), Merck, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, and others.
CD40/CD40L Inhibitors
Market
CD40/CD40L Inhibitors
Market, Target Population, Competitive Landscape, and Market Forecast
–
2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key CD40/CD40L inhibitors companies including Sanofi, UCB, Amgen, Eledon Pharmaceuticals, Kiniksa Pharmaceuticals, Memgen, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact UsShruti Thakur [email protected] +14699457679www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/neuromyelitis-optica-spectrum-disorder-market-poised-for-robust-expansion-through-2036–delveinsight-302714336.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…